{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T06:35:45Z","timestamp":1780814145156,"version":"3.54.1"},"posted":{"date-parts":[[2025,12,2]]},"group-title":"Neurology","reference-count":42,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,12,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ocrelizumab and natalizumab are commonly prescribed high-effectiveness disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS). However, no randomized clinical trial and few real-world studies have directly compared their effectiveness in reducing disability progression. Subtype classification and disability status are critical for multiple sclerosis (MS) research, but these data are often missing in electronic health records (EHRs), limiting robust real-world evidence generation.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare the effectiveness of ocrelizumab and natalizumab in two-year clinician-rated disability progression among RRMS patients using longitudinal registry-linked EHR data.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective cohort study.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>A large healthcare system that includes both academic and community practices.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Patients diagnosed with MS who initiated ocrelizumab or natalizumab between 2012 and 2020, with at least 6-month EHR data before treatment initiation and no prior exposure to other high-effectiveness DMTs.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Exposures<\/jats:title>\n                  <jats:p>Treatment with ocrelizumab vs natalizumab.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Measurements<\/jats:title>\n                  <jats:p>We developed an ensemble machine learning model to impute RRMS subtype and disability outcomes using structured and narrative EHR data. The primary outcome was moderate\/severe clinician-rated disability at 2 years (observed or imputed Expanded Disability Status Scale [EDSS]\u22654) after treatment initiation. We estimated the average treatment effects using semi-supervised doubly robust approach with comprehensive confounder adjustment and calibration to mitigate imputation bias. Covariates included standard demographic and clinical features such as baseline disability as well as knowledge graph-selected features. Sensitivity analyses used observed EDSS scores in registry-derived RRMS patients. Exploratory analyses included rituximab, another B-cell\u2013depleting therapy, with adjustments for differences in patient profiles.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among RRMS patients, those treated with ocrelizumab (n=543) had a significantly lower two-year risk of moderate\/severe disability compared with those treated with natalizumab (n=205) based on imputed outcomes (risk difference, \u20135.87%; 95% CI: \u201311.28% to \u20130.46%; p=0.033) after confounder adjustment. Sensitivity analyses yielded consistent findings using imputed or observed EDSS outcomes in registry-derived RRMS patients.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion and relevance<\/jats:title>\n                  <jats:p>In this real-world comparative effectiveness study using a novel semi-supervised doubly-robust framework, ocrelizumab was associated with a lower risk of disability progression than natalizumab among RRMS patients. This approach provides a roadmap for generating robust large-scale real-world evidence in settings of missing key inclusion features and outcomes.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2025.12.01.25341331","type":"posted-content","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:06:55Z","timestamp":1765278415000},"source":"Crossref","is-referenced-by-count":1,"title":["Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records Study"],"prefix":"10.64898","author":[{"given":"Feiqing","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA"},{"name":"Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Hou","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Morini","family":"Sweet","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Mass General Brigham, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Han","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Mass General Brigham, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-3200","authenticated-orcid":false,"given":"Katherine P.","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA"},{"name":"Division of Rheumatology, Inflammation, and Immunity, Mass General Brigham, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrun","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA"},{"name":"Division of Rheumatology, Inflammation, and Immunity, Mass General Brigham, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9897-4422","authenticated-orcid":false,"given":"Tanuja","family":"Chitnis","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mass General Brigham, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence T.","family":"Bourgeois","sequence":"additional","affiliation":[{"name":"Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA, USA"},{"name":"Pediatric Therapeutics and Regulatory Science Initiative, Computational Health Informatics Program (CHIP), Boston Children\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1500-2589","authenticated-orcid":false,"given":"Zongqi","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5379-2502","authenticated-orcid":false,"given":"Tianxi","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA"},{"name":"Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026010206201414000_2025.12.01.25341331v2.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01473-3"},{"key":"2026010206201414000_2025.12.01.25341331v2.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"2026010206201414000_2025.12.01.25341331v2.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"2026010206201414000_2025.12.01.25341331v2.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"2026010206201414000_2025.12.01.25341331v2.5","doi-asserted-by":"crossref","first-page":"e200094","DOI":"10.1212\/NXI.0000000000200094","article-title":"Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis","volume":"10","year":"2023","journal-title":"Neurology - Neuroimmunol Neuroinflammation"},{"key":"2026010206201414000_2025.12.01.25341331v2.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2022-000304"},{"key":"2026010206201414000_2025.12.01.25341331v2.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396"},{"key":"2026010206201414000_2025.12.01.25341331v2.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"2026010206201414000_2025.12.01.25341331v2.9","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00209-5"},{"key":"2026010206201414000_2025.12.01.25341331v2.10","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.150"},{"key":"2026010206201414000_2025.12.01.25341331v2.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.26858"},{"key":"2026010206201414000_2025.12.01.25341331v2.12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41746-025-01616-z","article-title":"Conformal prediction enables disease course prediction and allows individualized diagnostic uncertainty in multiple sclerosis","volume":"8","year":"2025","journal-title":"npj Digit Med"},{"key":"2026010206201414000_2025.12.01.25341331v2.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"2026010206201414000_2025.12.01.25341331v2.14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv258"},{"key":"2026010206201414000_2025.12.01.25341331v2.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078927"},{"key":"2026010206201414000_2025.12.01.25341331v2.16","doi-asserted-by":"crossref","first-page":"103333","DOI":"10.1016\/j.msard.2021.103333","article-title":"Temporal trends of multiple sclerosis disease activity: Electronic health records indicators","volume":"57","year":"2022","journal-title":"Mult Scler Relat Dis"},{"key":"2026010206201414000_2025.12.01.25341331v2.17","doi-asserted-by":"crossref","first-page":"e864","DOI":"10.1212\/NXI.0000000000000864","article-title":"Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity","volume":"7","year":"2020","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"2026010206201414000_2025.12.01.25341331v2.18","doi-asserted-by":"crossref","first-page":"e2134627","DOI":"10.1001\/jamanetworkopen.2021.34627","article-title":"Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis","volume":"4","year":"2021","journal-title":"Jama Netw Open"},{"key":"2026010206201414000_2025.12.01.25341331v2.19","doi-asserted-by":"crossref","unstructured":"Gan Z , Zhu W , Tang W , et al. Knowledge Graph-Guided Identification of Multiple Sclerosis and Therapeutic Trend Analysis: Real-World Evidence from Two Large Healthcare Systems. medRxiv 2025; 2025.11.12.25340116.","DOI":"10.1101\/2025.11.12.25340116"},{"key":"2026010206201414000_2025.12.01.25341331v2.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.02.012"},{"key":"2026010206201414000_2025.12.01.25341331v2.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-019-0227-6"},{"key":"2026010206201414000_2025.12.01.25341331v2.22","doi-asserted-by":"crossref","unstructured":"Xiong X , Sweet SM , Liu M , et al. Knowledge-Driven Online Multimodal Automated Phenotyping System. medRxiv 2025; 2023.09.29.23296239.","DOI":"10.1101\/2023.09.29.23296239"},{"key":"2026010206201414000_2025.12.01.25341331v2.23","doi-asserted-by":"publisher","DOI":"10.1373\/49.4.624"},{"key":"2026010206201414000_2025.12.01.25341331v2.24","doi-asserted-by":"publisher","DOI":"10.1136\/amiajnl-2011-000116"},{"key":"2026010206201414000_2025.12.01.25341331v2.25","first-page":"e143","article-title":"Surrogate-assisted feature extraction for high-throughput phenotyping","volume":"24","year":"2016","journal-title":"J Am Med Inform Assn"},{"key":"2026010206201414000_2025.12.01.25341331v2.26","doi-asserted-by":"publisher","DOI":"10.48550\/arxiv.1311.6063"},{"key":"2026010206201414000_2025.12.01.25341331v2.27","first-page":"170","article-title":"The UMLS project: making the conceptual connection between users and the information they need","volume":"81","year":"1993","journal-title":"Bull M\u00e9d Libr Assoc"},{"key":"2026010206201414000_2025.12.01.25341331v2.28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41746-021-00519-z","article-title":"Clinical knowledge extraction via sparse embedding regression (KESER) with multi-center large scale electronic health record data","volume":"4","year":"2021","journal-title":"npj Digit Med"},{"key":"2026010206201414000_2025.12.01.25341331v2.29","doi-asserted-by":"crossref","first-page":"100906","DOI":"10.1016\/j.patter.2023.100906","article-title":"LATTE: Label-efficient incident phenotyping from longitudinal electronic health records","volume":"5","year":"2024","journal-title":"Patterns"},{"key":"2026010206201414000_2025.12.01.25341331v2.30","doi-asserted-by":"crossref","first-page":"e16046","DOI":"10.1111\/ene.16046","article-title":"The Patient-Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis","volume":"31","year":"2024","journal-title":"Eur J Neurol"},{"key":"2026010206201414000_2025.12.01.25341331v2.31","doi-asserted-by":"crossref","first-page":"105594","DOI":"10.1016\/j.msard.2024.105594","article-title":"NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab","volume":"87","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2026010206201414000_2025.12.01.25341331v2.32","doi-asserted-by":"crossref","unstructured":"Yamout B , Alroughani R , Mohamed SFA , et al. Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study. J Neurol, Neurosurg Psychiatry 2025; jnnp-2024-335704.","DOI":"10.1136\/jnnp-2024-335704"},{"key":"2026010206201414000_2025.12.01.25341331v2.33","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06608-z"},{"key":"2026010206201414000_2025.12.01.25341331v2.34","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/acn3.52118","article-title":"A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis","volume":"11","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"2026010206201414000_2025.12.01.25341331v2.35","doi-asserted-by":"crossref","first-page":"e00537","DOI":"10.1016\/j.neurot.2025.e00537","article-title":"Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study","volume":"22","year":"2025","journal-title":"Neurotherapeutics"},{"key":"2026010206201414000_2025.12.01.25341331v2.36","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221142924"},{"key":"2026010206201414000_2025.12.01.25341331v2.37","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","year":"2024","journal-title":"J Neurol"},{"key":"2026010206201414000_2025.12.01.25341331v2.38","doi-asserted-by":"crossref","first-page":"104729","DOI":"10.1016\/j.msard.2023.104729","article-title":"Current evidence of rituximab in the treatment of multiple sclerosis","volume":"75","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"2026010206201414000_2025.12.01.25341331v2.39","doi-asserted-by":"crossref","first-page":"1500763","DOI":"10.3389\/fneur.2024.1500763","article-title":"Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study","volume":"15","year":"2025","journal-title":"Front Neurol"},{"key":"2026010206201414000_2025.12.01.25341331v2.40","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-10989-0"},{"key":"2026010206201414000_2025.12.01.25341331v2.41","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis","volume":"80","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026010206201414000_2025.12.01.25341331v2.42","doi-asserted-by":"crossref","first-page":"106564","DOI":"10.1016\/j.msard.2025.106564","article-title":"Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study","volume":"101","year":"2025","journal-title":"Mult Scler Relat Disord"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2025.12.01.25341331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T14:20:25Z","timestamp":1767363625000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2025.12.01.25341331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":42,"URL":"https:\/\/doi.org\/10.64898\/2025.12.01.25341331","relation":{},"subject":[],"published":{"date-parts":[[2025,12,2]]},"subtype":"preprint"}}